Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Obesity and Methamphetamine Use Disorder
NCT06745128Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in methamphetamine use disorder (MUD) and obesity, sponsored by UT Southwestern Medical Center. Primary endpoint: Self-reported use of methamphetamine at 36 weeks. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
methamphetamine use disorder (MUD)obesity
Beyond the preview
Go deeper on NCT06745128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745128.